| Literature DB >> 30651974 |
Meiling Li1, Xiaoli Wang1, Jiahui Wang1, Ruoming Tan1, Jingyong Sun2, Lei Li1, Jie Huang1, Jun Wu1, Qiuying Gu1, Yujin Zhao1, Jialin Liu1, Hongping Qu1.
Abstract
Objective: To determine whether infection-prevention and control (IPC) interventions can reduce the colonisation and infection of intensive care unit (ICU)-acquired carbapenem-resistant Klebsiella pneumoniae (CRKP) in a general ICU ward in China.Entities:
Keywords: Carbapenem-resistant Klebsiella pneumoniae; Catheter-related infection, intensive care unit; De-escalation; Incidence; Infection-prevention and control intervention
Mesh:
Substances:
Year: 2019 PMID: 30651974 PMCID: PMC6329090 DOI: 10.1186/s13756-018-0453-7
Source DB: PubMed Journal: Antimicrob Resist Infect Control ISSN: 2047-2994 Impact factor: 4.887
Interventions undertaken to curtail the epidemic spread of CRKP in 4 cumulative stages a
| Intervention | Description | Date begun |
|---|---|---|
| Baseline period | No intervention and regular surveillance cultures | Jan 2013- June 2013 |
| Period 1 | 1. Active surveillance cultures | July 2013–June 2014 |
| 2.1 First level interventions | ||
| • contact precautions | ||
| 2.2 Second level interventions | ||
| • contact precautions | ||
| IPC interventions | 2.3 Third level interventions | |
| • disinfection and sterilization | ||
| 3. Target bundles interventions | ||
| • intravascular catheter-related infection | ||
| Period 2 | 1. Active surveillance cultures | July 2014–June 2015 |
| Modified | + Enhanced external medical staff education | |
| 2.1 First level interventions (as Period 1) | ||
| 3. Target bundles interventions (as Period 1) | ||
| Period 3 | Follow up period 2 | July 2015–June 2016 |
aThe procedures of infection control interventions are explicated in detail in the section of Materials and Methods
IPC Infection prevention and control, CRKP Carbapenem-resistant Klebsiella pneumoniae
Fig. 1The procedures of (Modified) de-escalation interventions in period 2 and 3. Patients were active surveillance culture (ASC) for pathogens colonization and infection twice a week when admitted to the ICU, and assesse the risk factors of MDR bacteria colonization and infection immediately. For patients were defined infection/colonization with MDR pathogens, or came from clinical department with high prevalence of MDR bacteria before admitted to ICU, with invasive devices and damaged skin barrier such as endotracheal intubation, central venous catheter and urinary catheter etc., first level interventions measures were taken. For patients came from clinical department with low detection rate of MDR bacteria and just infected/colonized with common pathogens before admitted to ICU, second level interventions were taken. However, patients without bacteria infection/colonization or high risk factors, simple third level interventions were implemented. When patients in first level interventions have 2 consecutive negative tests which should be carried out over at least 1 week, descend to second level interventions. When continuous twice ASC negative results for second level patients, descend to third level interventions, and upgrade to first level interventions once MDR bacteria was detected during their ICU stay
Clinical characteristics of the ICU patients, according to study period
| Variable | Baseline period | Period 1 | Period 2 | Period 3 | |
|---|---|---|---|---|---|
| General characteristics | |||||
| Patients (no.) | 74 | 187 | 222 | 146 | |
| Age (yr), mean ± SD | 63 ± 17 | 62 ± 18 | 61 ± 18 | 63 ± 19 | 0.869 |
| Male sex (%) | 52(70.3%) | 114(61%) | 134(60.4%) | 90(61.6%) | 0.476 |
| APACHEII score, mean ± SD | 15 ± 7 | 15 ± 7 | 16 ± 8 | 19 ± 9 | 0.001 |
| Chronic disease | |||||
| Malignancy(%) | 29(39.2%) | 90(48.1%) | 108(48.6%) | 59(40.4%) | 0.249 |
| Chronic obstructive pulmonary disease(%) | 3(4.1%) | 6(3.2%) | 13(5.9%) | 8(5.5%) | 0.591 |
| Diabetes(%) | 12(16.2%) | 24(12.8%) | 35(15.8%) | 20(13.7%) | 0.811 |
| Hypertension(%) | 14(18.9%) | 55(29.4%) | 60(27%) | 54(37%) | 0.035 |
| Coronary heart disease(%) | 5(6.8%) | 10(5.3%) | 19(8.6%) | 7(4.8%) | 0.454 |
| Organ failure | |||||
| Congestive heart failure(%) | 4(5.4%) | 8(4.3%) | 26(11. 7%) | 19(13%) | 0.011 |
| Acute respiratory failure(%) | 12(16.2%) | 51(27.3%) | 72(32.4%) | 66(45.2%) | |
| Acute renal injury(%) | 16(21.6%) | 41(21.9%) | 50(22.5%) | 46(31.5%) | 0.147 |
| Acute gastrointestinal injury (%) | 5(6.80%) | 25(13.4%) | 25(11.3%) | 33(22.6%) | 0.003 |
| Hepatic insufficiency(%) | 6(8.1%) | 20(10.7%) | 26(11.7%) | 26(17.8%) | 0.123 |
| Exposure to antimicrobial therapy before CRKP colonization/infection | |||||
| Carbapenem | 44(59.5%) | 99(52.9%) | 115(51.8%) | 94(64.4%) | 0.078 |
| Cephalosporin antibiotics | 56(75.7%) | 135(72.7%) | 177(79.7%) | 94(64.4%) | 0.012 |
| Sulbactam/ cefoperazone | 12(16.2%) | 29(15.5%) | 43(19.4%) | 27(18.5%) | 0.749 |
| Mechanical ventilation before CRKP colonization/infection | |||||
| Tracheal intubation | 63(85.1%) | 162(86.6%) | 197(88.7) | 110(75.3%) | 0.004 |
| Tracheotomy | 11(4.9%) | 22(11.8%) | 23(10.8%) | 25(17.1%) | 0.318 |
| Days of mechanical ventilation, days, mean ± SD | 7 ± 14 | 7 ± 20 | 5 ± 14 | 10 ± 23 | 0.104 |
| Surgery or invasive devices before CRKP colonization/infection | |||||
| Surgery | 61(82.4%) | 160(85.6%) | 179(80.6%) | 103(70.5%) | 0.007 |
| Central line catheter | 71(95.9%) | 165(88.2%) | 180(81.1%) | 113(72.4%) | P < 0.001 |
| Thoracentesis | 9(12.2%) | 17(9.1%) | 23(10.4%) | 24(16.4%) | 0.184 |
| Abdominal paracentesis | 5(6.8%) | 25(13.4%) | 21(9.5%) | 18(12.3%) | 0.356 |
| Continuous renal replacement therapy | 1(1.4%) | 26(13.9%) | 22(9.9%) | 19(13%) | 0.022 |
| Indwelling urinary catheter | 70(94.6%) | 182(97.3%) | 218(98.2%) | 135(92.5%) | 0.027 |
Fig. 2Epidemic of observed monthly incidence rate of patients (No. of cases per 1000 ICU patient-days) colonized or infected with CRKP in the intensive care unit during the baseline and different intervention periods. Black bars show the incidence rate of ICU-acquired CRKP positivity, and gray bars represent the incidence rate of CRKP patients at ICU admission surveillance. Trend lines of ICU-acquired CRKP (No. of cases per 1000 ICU patient-days) for each period are shown in black solid bold type, showed a downward incidence rate trend from 10.08 to 2.84 after the implement of modified IPC interventions (P<0.05)
CRKP distribution and the incidence of ICU-acquired infections from different infection sites
| Variable | Baseline period | Period 1 | Period 2 | Period 3 | p |
|---|---|---|---|---|---|
| No. cases of total CRKP | 22 | 20 | 20 | 25 | |
| No. cases of ICU-on-admission CRKP | 1 | 3 | 2 | 12 | |
| No. cases of ICU-acquired CRKP | 21 | 17 | 18 | 13 | |
| Probable source of colonization/ infection of ICU-acquired CRKP | |||||
| Bloodstream n(%) | 3/21(14.3) | 6/17(35.3) | 1/18(5.6) | 1/13(7.7) | 0.11 |
| Respiratory tract n(%) | 4/21(19) | 3/17(17.6) | 5/18(27.8) | 5/13(38.5) | 0.555 |
| Skin and soft tissue n(%) | 13/21(61.9) | 7/17(41.2) | 12/18(66.7) | 3/13(23.1) | 0.058 |
| Urine tract n(%) | 1/21(4.8) | 1/17(5.9) | 0/18(0) | 4/13(25) | 0.073 |
| Incidence-ICU acquired | |||||
| Incidence of CRBSI (No. of cases per 1000 catheter days) | 2.54 | 2.44 | 0.43 | 0.41 | 0.352 |
| Incidence of VAP (No. of cases per 1000 ventilator-days) | 2.84 | 0.48 | 0.49 | 0.81 | 0.41 |
| Incidence of skin and soft tissue infections (No. of cases per 1000 ICU patient-days) | 3.40 | 0.99 | 1.46 | 0.47 | 0.531 |
| Incidence of catheter-associated urinary tract infection (No. of cases per 1000 catheter days) | 0 | 0 | 0 | 0.34 | 0.63 |
Monthly incidence rates of totally CRKP colonization/ infection and ICU-acquired CRKP (No. of cases per 1000 ICU patient-days)
| Intervention (period) | Incidence | Incidence | ||||||
|---|---|---|---|---|---|---|---|---|
| No. of cases per 1000 ICU patient-days (totally CRKP) | No. of cases per 1000 ICU patient-days (ICU-acquired CRKP) | |||||||
| Mean | Median | Pa | Pb | Mean | Median | Pc | Pd | |
| Baseline period | 10.33 ± 7.05 | 10.08 (4.43–17.46) | / | / | 9.88 ± 6.44 | 10.08 (4.43–16.43) | / | / |
| Period 1 | 5.05 ± 4.25 | 3.18 (2.98–6.18) | 0.014 | / | 4.30 ± 3.2 | 3.12 (2.98–5.40) | 0.024 | / |
| Period 2 | 4.94 ± 3.18 | 5.76 (2.77–6.34 | 0.013 | 0.945 | 4.47 ± 3.46 | 5.62 (0.69–6.34) | 0.032 | 0.9 |
| Period 3 | 5.88 ± 2.81 | 5.78 (3.52–8.47) | 0.037 | 0.577 | 3.05 ± 1.42 | 2.84 (2.80–2.89) | 0.021 | 0.032 |
aCompared with baseline period
bCompared with period 1
cCompared with baseline period
dCompared with period 1